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Abstract
Background: Hepatitis B virus is hyperendemic in Sudan. Our aim was to molecularly characterize hepatitis B virus
from Sudanese individuals, with and without liver disease, because genotypes play an important role in clinical
manifestation and treatment management.
Methods: Ninety-nine patients - 30 asymptomatic, 42 cirrhotic, 15 with hepatocellular carcinoma, 7 with acute
hepatitis and 5 with chronic hepatitis- were enrolled. Sequencing of surface and basic core promoter/precore
regions and complete genome were performed.
Results: The mean ± standard deviation, age was 45.7±14.8 years and the male to female ratio 77:22. The median
(interquartile range) of hepatitis B virus DNA and alanine aminotransferase levels were 2.8 (2.2-4.2) log IU/ml and 30
(19–49) IU/L, respectively. Using three genotyping methods, 81/99 (82%) could be genotyped. Forty eight percent of
the 99 patients were infected with genotype D and 24% with genotype E, 2% with putative D/E recombinants and 7%
with genotype A. Patients infected with genotype E had higher frequency of hepatitis B e antigen-positivity and higher
viral loads compared to patients infected with genotype D. Basic core promoter/precore region mutations, including
the G1896A in 37% of HBeAg-negative individuals, could account for hepatitis B e antigen-negativity. Pre-S deletion
mutants were found in genotypes D and E. Three isolates had the vaccine escape mutant sM133T.
Conclusion: Sudanese hepatitis B virus carriers were mainly infected with genotypes D or E, with patients infected
with genotype E having higher HBeAg-positivity and higher viral loads. This is the first study to molecularly characterize
hepatitis B virus from liver disease patients in Sudan.
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Background
Hepatitis B virus (HBV), the prototype member of the
family Hepadnaviridae is responsible for chronic infec-
tion of more than 240 million people worldwide [1], of
which 65 million reside in Africa [2].
Sudan is an African country with high HBV seropreva-
lence of greater than 8% HBsAg-positivity, ranging from
6.8% in central Sudan to 26% in southern Sudan [3-5].
HBV infection occurs in early childhood in southern
Sudan, with the infection increasing with age in northern
Sudan [3,6]. HBV was shown to cause 22% of fulminant
hepatitis cases in Sudan [7] and 18.5% of Sudanese blood
donors were exposed to the virus and 4% were infected at
the time of donation [8]. Nine genotypes of HBV, A–I,
with a distinct geographic distribution have been recog-
nized [9-11]. A tenth genotype, J, has been proposed but
was found only in one person [12]. Genotype A, D and E
circulate in Africa [2]. Genotype A prevails in southern,
eastern and central Africa. Genotype D is the dominant
genotype in northern Africa, whereas in western Africa
genotype E predominates. Subgenotypes have also been
identified within genotypes A and D [9,10].
Considering Sudan’s unique position and the flux of
people across its borders, it is important that the HBV
genotypes prevailing in this country are determined. In a
single study, in Sudanese asymptomatic blood donors, it
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was found that 57.5% were infected with genotype E,
40.5% with genotype D and 2% with subgenotype A2 [8].
Moreover, a diversity of genotypes are distributed in
neighbouring countries [2]: genotype D in Egypt to the
north [13], genotype E in the Democratic Republic of
Congo to the west [14] and genotype A in Kenya [15,16]
and Uganda [17] to the south. Knowledge of the genotypes
prevailing in Sudanese, with and without liver disease, is
important in treatment management, as well as disease
prognosis because genotypes play a role in both of these
aspects [18,19].
The Regional committee for the World Health
Organization (WHO) Eastern Mediterranean Region
(EMR), to which Sudan belongs, urged member states
to:
“Improve the epidemiological surveillance systems,
develop a hepatitis registry and implement serosurveys
in order to produced reliable data to guide prevention
and control measures and monitor impact of
preventive strategies” [20].
Thus our objective was to molecularly characterize




A cross-sectional, laboratory based study was conducted.
Ninety-nine sera were collected from HBsAg-positive
patients referred to the hepatology and general medical
clinics at IbnSina Hospital, Soba University Hospital and
Khartoum Teaching Hospital in Khartoum State be-
tween August 2008 and March 2009. The clinical report
forms (CRFs) were completed by qualified practitioners.
Informed consent was obtained from each patient in-
cluded in the study and the study protocol conforms to
the ethical guidelines of the 1975 Declaration of Helsinki
as reflected in a priori approval by the Human Ethics
Committees of the University of the Witwatersrand and
the University of Khartoum and the Ministry of Health
of Sudan. Alanine amino transferase (ALT) levels were
determined (reference range 5–40 IU/L) [21] and sam-
ples stored at -20°C. Chronic carriers were infected for
longer than six months and were classified as asymp-
tomatic carriers (ASCs) if they had normal ALT or
chronic hepatitis (CH) patients if they had abnormal
ALT. Acute hepatitis (AH) cases were diagnosed based
on clinical presentation (symptoms and clinical presence
of jaundice) plus high ALT and the presence of hepatitis
B core IgM antibody (HBcAbIgM). Clinical and ultra-
sonographic evidence were used to diagnose cirrhotic
(CR) and hepatocellular carcinoma (HCC) cases.
HBV serology
HBsAg was assayed using Monolisa™ HBsAg ULTRA and
HBeAg using Monolisa™ HBeAg-Ab PLUS kit (Bio-rad,
Hercules, CA). Anti-HBe and anti-HBc antibodies were
determined using HBeAg/Anti-HBe ELISA and Anti-HBc
Total ELISA, respectively (DIAsource ImmunoAssays S.A,
Nivelles, Belgium). Anti-HBc IgM was determined using
the ARCHITECTW kit (Abbott Diagnostics, Wiesbaden,
Germany).
DNA extraction
DNA was extracted from 200 μL of serum using QIAamp
DNA mini blood kit (QIAGEN GmbH, Germany),
according to manufacturer’s instructions, and eluted in
100 μL of buffer.
Real-time PCR quantification of HBV DNA
PCR primers, HBV-Taq1 and HBV-Taq2 covering a region
of the S gene (321 to 401 from the EcoRI site) with a
FAM/TAMRA labelled TaqMan BS-1 probe [22] were
used to quantify HBV DNA in an ABI 7500 Real Time
PCR System (Applied Biosystems, Foster City, Ca, USA).
A serial dilution of cloned plasmid DNA containing a sin-
gle genome of HBV DNA, with concentrations ranging
from 2 × 101 to 2 × 1011 IU/ ml, was used as template to
generate the standard curve. The second WHO Inter-
national Standard for HBV Nucleic Acid Amplification
Techniques (product code 97/750 National Institute for
Biological Standards and Controls (NIBSC); Hertfordshire,
UK), which has a final concentration of 106 IU/ml was
used as the internal standard. The standard curve, blank,
positive and negative controls, and samples were all tested
in duplicate. The measured IU/ml for each reaction was
calculated using the Ct (cycle threshold) value of each
PCR interpolated against the linear regression of the
standard curve. The lower detection limit of our assay
is ~20 IU/ ml. The conversion formula of IU =copies/4.7
was used [23-25].
Polymerase chain reaction (PCR) and restriction fragment
polymorphism assay (RFLP)
The basic core promoter/precore (BCP/PC) region and
complete S open reading frame (ORF) were amplified in a
MyCycler™ thermocycler (Bio-Rad, Hercules, Ca, USA)
using Promega Taq DNA polymerase (Promega, Madison,
WI). The BCP/PC PCR was amplified using a slight modi-
fication of the method described by Takahashi and col-
leagues [26] primers 1606 (+) (1606–1625 from EcoRI
site) and 1974 (−) (1974–1955 from EcoRI site) were used
for the first round (denaturation 94°C for 1 min, annealing
55°C for 1 min, extension 72°C for 2 min, 40 cycles) and
1653(+) (1653–1672 from EcoRI site) and 1959(−) (1959–
1940 from EcoRI site) for the second round, with the iden-
tical cycling conditions as the first-round PCR [25,27]. A
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nested PCR was carried out to amplify the complete S
ORF : primers 2410(+) (2410–2439 from EcoRI site) and
1314(−) (1314–1291 from EcoRI site) were used for the
first round (denaturation 94°C for 1 min, annealing 66°C
for 1 min, extension 72°C for 3 min, 40 cycles) and 2451
(+) (2451–2482 from EcoRI site) and 1280 (−) (1280–1254
from EcoRI site) for the second round (denaturation 94°C
for 1 min, annealing 65°C for 1 min, extension 72°C for 3
min, 40 cycles) [27]. Another nested PCR reaction was
carried out to amplify a short region of the S (459–710
from EcoRI site) to determine the genotype: primers 255
(+) (253–275 from EcoRI site) and 759 (−) (759–739 from
EcoRI site) were used for the first round (denaturation 94°C
for 30 sec, annealing 56°C for 40 sec, extension 72°C for 1
min, 40 cycles) and [459(+) (460–480 from EcoRI site)] and
[710(−) (711–691 from EcoRI site)] for the second round
(denaturation 94°C for 30 sec, annealing 56°C for 40 sec,
extension 72°C for 50 sec, 40 cycles) [28]. When the
complete S ORF and the short S could not be amplified, a
RFLP assay was used to determine the genotype of the
HBV isolates. Primers P7 (256–278 from EcoRI site) and P8
(796–776 from EcoRI site) were used to amplify nucleotides
256–796 of the S region. The amplicon was then cleaved
using restriction enzymes HinfI and Tsp509I, in separate re-
actions, to give the characteristic RFLP patterns for the dif-
ferent genotypes [29]. The complete genome was amplified
using a single amplification method with primers P1
(1821–1841 from EcoRI site) and P2 (1825–1806 from
EcoRI site), with modifications in the cycling conditions
[30]. Initial denaturation at 98°C for 1 min, 80°C for 30 sec
followed by adding the polymerase mix, 98°C for 1 min,
then 35 cycles of: 98°C for 10 sec, 57°C for 30 sec and 72°C
for 1 min.
Sequencing
The BigDye Terminator v3.0 Cycle Sequencing Ready Re-
action Kit (Applied Biosystems., Foster City, USA) was
used and sequencing performed using the ABI 3130XL
Genetic analyzer (Applied Biosystems, Foster City, CA). In
addition to sequencing primers: 2497F (2497–2516),
3188F (3188–3206) and 591F (591–611) used previously
[27,31], four new primers: 1069F (1069–1088) (5′- TGT
ATT CAA TCT AAG CAG GC-3′), Post-Bgl III (2000–
2017) (5′-CCG ATA CAG AGC TGA GGC-3′), 2022F
(2022–2041) (5′-CCT TAG AGT CTC CTG AGC AT-3
′), 2480R (2461–2480) (5′-CAC CTT ATG AGT CCA
AGG AA-3′), were used to sequence the complete gen-
ome. All positions are numbered from the EcoRI site of
genotype A (AY233286). The three overlapping fragments
of the complete S, and the 7 fragments of the complete
genome thus obtained, were assembled using the Frag-
ment Merger Tool [32]. Sequences were deposited in
GenBank, accession numbers KF170739-KF170812.
Phylogenetic analysis
Neighbour-joining using MEGA5 [33] or PHYLIP (Phyl-
ogeny inference package version 3.69) or DNADIST con-
secutively with NEIGHBOR were used to generate
dendrograms [34].
Analysis for intergenotypic recombination
SimPlot 3.5.1©, an interactive 32-bit software program,
that plots distances (or similarity) versus position [35] was
used to show recombination in isolate SDAC031 [33].
Results
HBV serology and viral loads
Of the 99 patients, 77 were males and 22 were females.
Mean age ± standard deviation (SD) was [45.7±14.8] years.
All sera were HBsAg- and anti-HBc-positive; 12 were
HBeAg-positive/anti-HBe-negative, 75 were HBeAg-
negative/anti-HBe-positive, and 12 had neither HBeAg
nor anti-HBe. All patients were HBV DNA-positive, with
a median (interquartile range) (IQR) viral load of [2.8
(2.2–4.2)] log IU/ml and ALT median (IQR) level was [30
(19–49)] IU/L (reference range 5–40 IU/L) [21].
Clinical and demographic characteristics
The 99 cases were classified into five clinical groups:
HCC (n=15), CR ( n=42), ASCs (n=30), AH ( n=7) and
CH ( n=5). The HCC patients were significantly older
than patients in the other groups (p <0.05) and the AH
patients were significantly younger (p <0.05). The ALT
levels were the highest in the AH (p <0.05) (Table 1).
The median viral load of HBeAg-positive patients [6.99
(5.63–7.57) log IU/ml] was significantly higher than in
HBeAg-negative patients [2.55 (2.09–3.42) log IU/ml]
(p<0.05). The viral loads and frequency of HBeAg-
positivity did not differ between clinical groups.
HBV genotyping and phylogenetic analysis
In order to maximize the number of isolates genotyped,
three methods were used sequencially (Figure 1).
81 HBV isolates were thus successfully genotyped
Firstly, 53 of 99 were genotyped using amplification and
sequencing of the complete S (2848–835 from EcoRI),
followed by phylogenetic analysis (Figure 2), secondly,17
of 46 were genotyped by amplification and sequencing of
a short S fragment (520–704 from EcoRI), followed by
phylogenetic analysis (trees not shown) and thirdly,11 of
29 by RFLP analysis.
The relatively longer amplicon of the S region of 2.1
kb in length, compared to the shorter regions used for
the short S and RFLP amplifications, meant that not all
samples could be amplified in the longer region success-
fully. 18.2% (18/99) could not be genotyped using any of
the three methods. No sequences could be obtained for
10 of these isolates and for the remaining 8 only the
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BCP/PC region was sequenced, which is not sufficient to
differentiate between genotypes D and E.
The genotype distribution in the 81 samples was 59%
genotype D: 30% genotype E: 8.5% genotype A: 2.5% pu-
tative D/E recombinant. If we include the 18 samples
that could not be genotyped, 48.5% (48/99) were infected
with genotype D, 24.2% (24/99) with genotype E, 7.1%
(7/99) with genotype A and 2% (2/99) were infected with
a putative D/E recombinant.
Phylogenetic analysis of the complete S region allowed
for further classification into subgenotypes (Figure 2). Based
on the recently suggested classification system [33], 23 of
31 genotype D isolates belonged to subgenotype D1 (74%),
3 to D2 (10%), 1 to D3 (3%) and 4 to D6 (13%). One geno-
type A isolate belonged to subgenotype A1 (Figure 2).
The complete genome of four isolates was amplified,
two (SDAC024 and SDAC031) belonged to genotype D
and two (SDAC047 and SDAC125) to genotype E.
Table 1 Demographic and clinical characteristics of 99 patients
Clinical status
HCC (15) ASC (30) CR (42) AH (7) CH (5)
Male: Female 13:02 22:08 37:05:00 02:05 03:02
Age mean ±SD 57.3±13.8a 42.8±15.1 46.5±12.9 32.1±12.4a 37.6±41.0
ALT median IU/L (IQR) 40 (24–50) 22 (18–33) 27 (18–45) 461 (312–834)a 38 (29–47)
HBeAg positive (%) 2 (13.3) 2 (6.7) 7 (16.7) 1 (14.3) 0
Log viral loads 3.8 2.5 2.8 3 2.1
IU/ml median (IQR) (2.4-4.7) (2.2–3.3) (2.2-5.3) (2.2-3.8) (2.0-3.6)
HCC Hepatocellular carcinoma, ASC Asymptomatic carriers, CR Cirrhosis, AH Acute hepatitis, CH Chronic hepatitis.
aSignificant difference with other groups.
Figure 1 Algorithm summarizing protocol and results of the molecular characterization of BCP/PC region and genotyping of HBV.
a Three isolates showed genotype D based on S region and genotype A based on BCP/PC region.
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Although the genotypes determined using the complete
genome agreed with that determined using the S ORF,
there was a discrepancy in the subgenotype classification
of SDAC031. Using phylogenetic analysis of the complete
S, it clustered as an outlier of subgenotype D4, whereas fol-
lowing complete genome phylogenetic analysis it clustered
with D6 (Figure 2). Simplot analysis showed SDAC031 to
be a recombinant of D6 and D4. By mapping the inform-
ative sites, we estimated the transition positions between
D6 and D4 (Figure 3). The genotype E isolates (SDAC047
and SDAC125) clustered together when the complete S
was compared, whereas they separated into different clades
in the complete genome analysis (data not shown).
Although the majority of subgenotype D isolates showed
the respective distinct subgenotype amino acids signatures
[33], there were exceptions. SDAC031 (D6) showed
preS2I42T, spV59F and rtT237P. SDAC085 (D6) had
spV59S. SDAC107 (D6) had preS2I42T and rtT237P. All
17 genotype E isolates had genotype E signature amino
acid motifs.
Comparison of patients infected with genotypes D and E
Because the majority were infected with either genotype D
or E, further analyses compared the patients’ clinical and
virological features infected with these genotypes. No sig-
nificant difference was observed in gender, age, ALT and
Figure 2 A rooted phylogenetic tree of 53 complete S sequences of HBV obtained from Sudanese liver disease patients (shaded in
box) with 104 reference HBV sequences, using neighbour-joining. Bootstrap statistical analysis was performed using 1000 datasets, indicated as
percentages on the nodes. The sequences are labeled by their accession numbers and country. [AUS, Australia; CMR, Cameron; CAN, Canada; CAR,
Central African Republic; CHN, China; COV, Côte d’Ivoire; DRC, Democratic Republic of Congo; EGP, Egypt; EST, Estonia; FR, France; GHN, Ghana; GER,
Germany; HAI, Haiti; IND, India; IRN, Iran; ITA, Italia; JAP, Japan; KAZ, Kazakhstan; LEB, Lebanon; MAD, Madagascar; MLY, Malaysia; MLW, Malawi; NAM,
Namibia; NIG, Niger; PAK, Pakistan; PAP, Papua New Guinea/Indonesia; POL, Poland; RUS, Russia; RWD, Rwanda; SRB, Serbia; SOM, Somalia; SA, South
Africa; SPN, Spain; SDW, Sweden; TNZ, Tanzania; TAJ, Tajikistan; TUN, Tunisia; TUR, Turkey; UGN, Uganda; UK, United Kingdom; USA, United States; UZK,
Uzbekistan ]. The letters, A, D and E, represent the genotypes and the numbers the subgenotypes. A rooted phylogenetic tree of the complete
genome of SDAC 031 (shaded) relative to 17 reference HBV sequences, using neighbour-joining is shown in the left hand box. When the complete
genome was analyzed SDAC031 clustered with D6 whereas when the S region alone was analyzed it clustered with D4.
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clinical groups of patients infected with either genotype.
Patients infected with genotype E, showed a significantly
higher frequency of HBeAg-positivity compared to pa-
tients infected with genotype D (p <0.05) and HBV DNA
levels in patients infected with genotype E were signifi-
cantly higher (p <0.05) (Table 2).
Molecular characterization of HBV isolates
Analysis of basic core promoter/precore (BCP/PC) region
Of the 70 isolates amplified and sequenced in the BCP/PC
region, 62 amplfied in the S region and thus had genotype
assignments. 57 isolates belonged to either genotype D or
E, and 5 to genotype A. Seven of 8 genotype D or E isolates
Figure 3 Graphs show bootscanning values of query sequence SDAC031 to representative sequences of subgenotypes D1 to D6 and
outgroup, genotype F. Graphs were generated using Simplot version 3.5.1© with window size: 200 bp, step size 20 bp, gap-strip off, 100
bootstrap replicates, Kimura transition/transversion ratio:2 and NEIGHBOR. Dashed vertical lines indicate breakpoints. The numbers of informative
sites, which are shared by the isolate with subgenotype D4 are shown above and with subgenotype D6, below, on the right hand side of the
four-member trees representing these sites. The genomic regions belonging to subgenotype D4 are shaded in grey.
Table 2 Clinical and demographic characteristics of 81 patients, for which HBV was genotyped
Clinical status Demographic Biochemical and virological
characteristics characteristics








Genotype D (%) 4(30.7) 14(58.3) 23(69.7) 4(57.1) 3(75) 38:10 44.6 ±15.1 29 (19–57) 4 (8.3) 2.8 (2.0-3.9)
Genotype E (%) 6(46.2) 6(25) 8(24.3) 3(42.9) 1(25) 17:07 49.3 ±14.3 29 (18–65) 7 (29.2)a 4 (2.6-5.7)a
Genotype D/E (%) 1(7.7) 0 1(3) 0 0 2:0 56.5 ±7.0 NA 0 2.4 (2.3-2.41)
Genotype A (%) 2(15.4) 4(16.7) 1(3) 0 0 5:2 38.14 ±14.51 33 (28–54) 1 (14.3) 2.6 (2.3-3.9)
HCC, Hepatocellular carcinoma; ASC, Asymptomatic carriers; CR, Cirrhosis; AH, Acute hepatitis, CH, Chronic hepatitis.
aSignificant difference between patients infected with genotype D or E.
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from HBeAg-positive patients had wild-type BCP/PC, and
one (SDAC118) had G1764T. The mutations found in
genotype D or E isolates from HBeAg-negative individuals
are shown in Figure 4: 15/49 genotype D or E isolates from
HBeAg-negative sera, had wild-type BCP/PC region. In
22/49 HBeAg-negative sera, the absence of HBeAg was as
a result of missense mutations affecting the translation of
the HBeAg precursor: 18 had the classical stop codon mu-
tation G1896A (p< 0.05, when comparing isolates from
HBeAg-negative and –positive sera) and 4 had initiation
codon mutations, 2 A1814T and 2 T1815C. A1762T/
G1764A was found in 11 G1896A mutants and in one
T1815C mutant. Six isolates from HBeAg-negative sera had
A1762T/G1764A alone. The Kozak sequence was GCAC
at 1809–1812 in 45 isolates, GTAC in isolate SDAC 121
and TCAT with 1858C and 1888A in isolates SDAC018,
SDAC090 and SDAC091. SDAC050 had 1858C with
1888A alone.
Although generally the BCP/PC region cannot be used
to determine specific genotypes, genotype A and its
subgenotypes can be differentiated from genotypes D or
E because of specific sequence characteristics. One
genotype A isolate from a HBeAg-positive patient,
(SDAC108) had A1762T/G1764A. From the BCP/PC se-
quences it was deduced that this isolate belonged to
subgenotype A2, because it had GCAC at 1809–1812,
1858C and 1888G. The other four genotype A isolates
were from HBeAg-negative individuals. These isolates,
SDAC062, SDAC073 SDAC100 and SDAC113, belonged
to subgenotype A1 because they had TCAT at 1809–
1812, 1858C and 1888A. One isolate had wild-type BCP/
PC region, two had A1762T/G1764A, one with G1862T
and the fourth isolate had G1862T alone. No significant
association was found between the BCP/PC mutations
and genotypes or clinical groups.
Analysis of the pre-S1, pre-S2, Surface and Polymerase regions
The complete S region was sequenced for 53 isolates and
pre-S mutations were detected in 14 (26%). Four muta-
tional patterns were identified: pre-S1 deletions (2/14;
14%), pre-S2 start codon mutation (4/14; 29%), pre-S2
start codon mutation with pre-S2 deletion (1/14; 7%) and
pre-S2 deletion alone (7/14; 50%) (Table 3). Transcription
regulatory box domain substitutions [CCAAT→CTAAT]
(803–807 from EcoRI site), were found in two isolates
(SDAC095 genotype E and SDAC098 genotype D). Three
cis-acting elements mutations were found: C1092T in the
Enhancer I in one isolate, C1155T in the Enhancer I in 6
isolates and T3109G S2 promoter in 2 isolates. PreS2F22L
was found in 6 genotype E and three genotype D isolates.
The vaccine escape mutation, sM133T, was observed in
genotype E isolates, SDAC022, SDAC067 and SDAC088.
In the reverse transcriptase domain of the polymerase, the
following mutations were detected: rtA194T in SDAC049
(genotype D), rtV207M in SDAC020 (genotype D), rtS213T
in SDAC063 and SDAC098 (genotype D), SDAC002,
SDAC121 and SDAC004 (genotype E), rtV214A in
SDAC059 (genotype E) and rtS215Q in SDAC049 and
SDAC090 (genotype D).
Discussion
In Sudan, where HBV is hyperendemic, little is known
about the genotypes and mutants of HBV in liver disease
patients. Thus HBV, from 99 patients, belonging to five
clinical groups, were studied. Of the 81 samples that were
successfully genotyped, close to 60% belonged to genotype
D whereas the opposite was true in Sudanese blood do-
nors, where genotype E prevailed (57%) [8]. HCC patients
in this study, who were infected with either genotype D or
E, were significantly older than ASC, CH, AH, CR patients,
with the AH patients being significantly younger (Table 1).
Figure 4 Mutation distribution in the basic core promoter/precore region, at 11 loci of interest (1762, 1764, 1809–1812, 1814, 1815,
1858, 1888 and 1896), of 49 genotype D or E HBV isolates from HBeAg-negative patients. Boxed motif represents the wild- type of
genotypes D or E. Data were obtained using the Mutation Reporter Tool [36]. Mutations are shaded in grey. The frequency of the mutational
patterns did not differ between genotype D and E.
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This differs from HCC patients, infected with genotype A,
who develop cancer at a significantly younger age [28]. In
agreement with others [37,38], the HCC group had the
highest median viral load. High viral loads have been im-
plicated as a risk factor for HCC development [39].
In agreement with the study in Sudanese blood donors
[8], the predominant subgenotype of D was D1. Further-
more, following phylogenetic analysis of the complete S
region, two isolates, which lacked the 33 nucleotide dele-
tion, characteristic of genotype D, were genotype D/E
recombinants [8,33,40]. Following phylogenetic analysis
of the complete S, one isolate belonged to subgenotype
A1, and from the BCP/PC sequence, a further four were
deduced to belong to subgenotype A1 [41]. This is the
first time that subgenotype A1 has been identified in
Sudan whereas a previously sequenced genotype A iso-
late from Sudan belonged to A2 [8]. Subgenotype A1
circulates in southern and eastern Africa and Southern
Asia and A2 is found in Northern and Central Europe
and North America [42].
Discrepant results were obtained in the subgenotype as-
signment of SDAC031 when the complete S and complete
genome were analyzed. The complete S clustered as an
outlier of D4 whereas the complete genome clustered
with D6. D4 and D6 are phylogenetically closely related
(Figure 2). Further analysis using Simplot, showed that it
was a D6/D4 recombinant (Figure 3) and the majority of
signature amino acids were of D6, with the exception of a
number of amino acids, which were of D4 [33]. Geograph-
ically, D6 is distributed in theMaghreb and Madagascar,
whereas D4 in the Americas and Australia. It is possible
that D4 originated in Africa but has subsequently been re-
placed by other subgenotypes of D and the recombinant is
a remnant of the original strain/s.
The HBV genotypes show a distinct geographical dis-
tribution in Africa, with genotype D predominating in
the North, genotype E in the West and genotype A in
the South-East [9]. This is the first study to describe the
co-circulation of genotypes D and E in liver disease pa-
tients and to allow the comparison of patients infected
with these two genotypes. In agreement with a study
carried out in Sudanese blood donors [8], viral loads
were significantly higher in genotype E-infected patients
compared to genotype D-infected, with patients infected
with genotype E, showed a significantly higher frequency
of HBeAg-positivity. The small size of HBeAg allows it
to traverse the placenta and elicit HBe/HBcAg-specific T
helper cell tolerance in utero [43]. Thus babies born to
HBeAg-positive mothers have high chronicity rates than
those born to HBeAg-negative mothers [43]. The high
frequency of HBeAg-positivity in mothers infected with
genotype E, would lead to its vertical transmission and
Table 3 Pre-S region mutations and deletions
Clinical group Genotype Pre-S2 S tart codon Deletions
Region Nucleotides Amino acids Region and functions affected
ID Size Position Size position
SDAC024 CR D ATG Pre-S2 21 35-55a 7 16-22a
SDAC048 CR D ATG Pre-S1 72 2998-3069 24 51-74 S promoter, Transactivator domain
SDAC083 CR D ATG Pre-S2 21 35-55 7 16-22
SDAC097 CR D GTGb Pre-S 2 9 45- 53 3 19-21
SDAC098 CH D ATG Pre-S1 18 3129-3146 6 94-99 Hsc70 binding site, CCAAT binding factor (CBF)
binding site, Cytosolic anchorage determinant (CAD)
SDAC112 ASC D ATG Pre-S2 6 49-54 2 20-21
SDAC118 CR D ATG Pre-S2 54 4-57 18 5 to 22 pHSA binding site, Viral secretion
SDAC107 CR D ATA - - - - - -
SDAC090 CR D ATA - - - - - -
SDAC058 CR E ATG Pre-S2 9 58-66c 3 20-22c Transactivator domain
SDAC059 HCC E GTG Pre-S2 12 52-63 4 18-21 Transactivator domain
SDAC088 HCC E ATG Pre-S2 12 52-63 4 18-21 Transactivator domain
SDAC095 HCC E ATG Pre-S2 15 52-66 5 18-22 Transactivator domain
SDAC067 ASC E GTG - - - - - -
SDAC113 ASC A ACA - - - - - -
a nucleotide or amino acid position relative to genotype D (GU456684).
b mutant pre-S2 start codon italicized.
c nucleotide or amino acid position relative to genotype E (AB205191).
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explain the high prevalence and geographical restriction
of this genotype in Africa and to African emigrants to
other regions [14]. The higher HBeAg-positivity seen in
individuals infected with genotype E, could confer toler-
ance and less serious clinical manifestations than geno-
type D, where HBeAg-positivity was lower. This could
explain why genotype E prevails in the Sudanese blood
donors [8], whereas genotype D prevailed in the liver
disease patients in the present study.
The majority of the HBeAg-negativity was as a result of
the classical G1896A, which abolishes HBeAg expression
[44] and occurs in genotype D or E but not A because the
encapsidation signal secondary structure precludes this
mutation in genotype A [45,46]. Other mutations includ-
ing transcriptional A1762T/G1764A and translation initi-
ation mutations were responsible of HBeAg-negativity in a
number of patients. Three isolates had TCAT instead of
GCAC in the Kozak sequence preceding the precore
initation codon and can affect HBeAg expression at the
translational level [47]. This Kozak mutation occurred to-
gether with 1858C and 1888A (pattern 5, Figure 4), which
are characteristics of subgenotype A1 [41]. One isolate has
1858C and 1888A alone. However, following phylogenetic
analysis of the complete S region, these four isolates were
found to belong to genotype D. It is possible that these pa-
tients were co-infected with genotypes D and A or with D/
A recombinants. These possibilities can only be discrimi-
nated by complete genome cloning and sequencing.
Four different pre-S mutational patterns were identified
(Table 3). In genotype E, pre-S2 deletions were found
mainly in HCC patients, whereas in genotype D, the dele-
tion mutants were from non-HCC patients. However, the
numbers were small to reach any firm conclusions. Pre-S
deletion mutants were found in genotype E isolates
from ASCs from Guinea [48] and Sudan [8]. Pre-S
deletion/mutations affect the progression to serious
liver disease in patients infected with either genotype
B or C [49].
Six genotype E and three genotype D isolates had
preS2F22L, which is a risk factor for HCC [50,51]. Inter-
estingly, three genotype E isolates had the sM133T mu-
tation, which could possibly compromise antibody
neutralization and may represent potential vaccine
escape mutants [52]. However, because these individuals
were not vaccinated for HBV, this mutation may have
emerged as a result of host immune pressure. The
reverse transcriptase mutations rtA194T, rtV207M,
rtS213T, rtV214A and rtS215Q detected in the present
study are neither primary resistance mutations, nor
have they ever been seen in overt resistance during ther-
apy [53]. When mutations rtA194T, rtV207M rtS213T
rtV214A and rtQ215S were tested in our sensitive and
reliable in vitro resistance test system, the mutants
showed no resistance to lamivudine (LMV), entecavir
(ETV), adenofovir (ADF) and tenofovir (TDF). (Glebe
et al., unpublished observations).
Conclusion
This is the first study to molecularly characterize HBV from
Sudanese liver disease patients, who were predominantly
infected with genotypes D and E, allowing comparison of
the effect of these genotypes on clinical manifestation in
the same ethnic group.
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